Suppr超能文献

改善困难外周静脉穿刺需要思考、培训和技术(DART):一项阶梯式、集群随机对照试验方案。

Improving difficult peripheral intravenous access requires thought, training and technology (DART): a stepped-wedge, cluster randomised controlled trial protocol.

机构信息

The School of Nursing, Midwifery and Social Work, The University of Queensland, Brisbane, Australia.

Centre for Clinical Research, The University of Queensland, Brisbane, Australia.

出版信息

BMC Health Serv Res. 2023 Jun 7;23(1):587. doi: 10.1186/s12913-023-09499-0.

Abstract

BACKGROUND

Peripheral intravenous catheters (PIVCs) are the most used invasive medical device in healthcare. Yet around half of insertion attempts are unsuccessful leading to delayed medical treatments and patient discomfort of harm. Ultrasound-guided PIVC (USGPIVC) insertion is an evidence-based intervention shown to improve insertion success especially in patients with Difficult IntraVenous Access (BMC Health Serv Res 22:220, 2022), however the implementation in some healthcare settings remains suboptimal. This study aims to co-design interventions that optimise ultrasound guided PIVC insertion in patients with DIVA, implement and evaluate these initiatives and develop scale up activities.

METHODS

A stepped-wedge cluster randomized controlled trial will be conducted in three hospitals (two adult, one paediatric) in Queensland, Australia. The intervention will be rolled out across 12 distinct clusters (four per hospital). Intervention development will be guided by Michie's Behavior Change Wheel with the aim to increase local staff capability, opportunity, and motivation for appropriate, sustainable adoption of USGPIVC insertion. Eligible clusters include all wards or departments where > 10 PIVCs/week are typically inserted. All clusters will commence in the control (baseline) phase, then, one cluster per hospital will step up every two months, as feasible, to the implementation phase, where the intervention will be rolled out. Implementation strategies are tailored for each hospital by local investigators and advisory groups, through context assessments, staff surveys, and stakeholder interviews and informed by extensive consumer interviews and consultation. Outcome measures align with the RE-AIM framework including clinical-effectiveness outcomes (e.g., first-time PIVC insertion success for DIVA patients [primary outcome], number of insertion attempts); implementation outcomes (e.g., intervention fidelity, readiness assessment) and cost effectiveness outcomes. The Consolidated Framework for Implementation Research framework will be used to report the intervention as it was implemented; how people participated in and responded to the intervention; contextual influences and how the theory underpinning the intervention was realised and delivered at each site. A sustainability assessment will be undertaken at three- and six-months post intervention.

DISCUSSION

Study findings will help define systematic solutions to implement DIVA identification and escalation tools aiming to address consumer dissatisfaction with current PIVC insertion practices. Such actionable knowledge is critical for implementation of scale-up activities.

TRIAL REGISTRATION

Prospectively registered (Australian and New Zealand Clinical Trials Registry; ACTRN12621001497897).

摘要

背景

外周静脉导管(PIVC)是医疗保健中使用最广泛的侵入性医疗器械。然而,约有一半的插入尝试不成功,导致医疗治疗延迟和患者不适或受伤。超声引导下的 PIVC(USGPIVC)插入是一种基于证据的干预措施,已被证明可以提高插入成功率,尤其是在有困难静脉通路(BMC Health Serv Res 22:220,2022)的患者中,然而,在一些医疗保健环境中,其实施情况仍不理想。本研究旨在共同设计优化超声引导下 PIVC 插入的干预措施,在有 DIVA 的患者中实施和评估这些干预措施,并开展扩大活动。

方法

本研究将在澳大利亚昆士兰州的三家医院(两家成人医院,一家儿科医院)进行一项逐步楔形集群随机对照试验。该干预措施将在 12 个不同的集群(每个医院 4 个)中推出。干预措施的制定将以 Michie 的行为改变车轮为指导,旨在提高当地工作人员的能力,为 USGPIVC 插入的适当和可持续采用提供机会和动力。符合条件的集群包括每周通常插入 >10 个 PIVC 的所有病房或部门。所有集群都将在对照(基线)阶段开始,然后,每个医院的一个集群将每两个月逐步推进到实施阶段,在该阶段,将推出干预措施。实施策略由当地研究人员和咨询小组根据具体情况评估、员工调查和利益相关者访谈进行定制,并通过广泛的消费者访谈和咨询提供信息。结果测量符合 RE-AIM 框架,包括临床效果结果(例如,DIVA 患者首次 PIVC 插入成功率[主要结果],插入尝试次数);实施结果(例如,干预一致性、准备情况评估)和成本效果结果。将使用实施研究综合框架报告干预措施,包括实施方式;人们如何参与和对干预措施做出反应;背景影响以及干预措施背后的理论如何在每个地点实现和交付。将在干预后三至六个月进行可持续性评估。

讨论

研究结果将有助于确定系统解决方案,以实施 DIVA 识别和升级工具,旨在解决消费者对当前 PIVC 插入实践的不满。这种可操作的知识对于实施扩大活动至关重要。

试验注册

前瞻性注册(澳大利亚和新西兰临床试验注册处;ACTRN12621001497897)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验